Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment

Takeru Maekawa¹, Toru Miyake¹*, Masaji Tani¹ and Shinji Uemoto²

¹Division of Gastrointestinal, Breast, Pediatric, and General Surgery, Department of Surgery, Shiga University of Medical Science, Otsu, Japan, ²Shiga University of Medical Science, Otsu, Japan

Ascorbic acid has attracted substantial attention for its potential antitumor effects by acting as an antioxidant in vivo and as a cofactor in diverse enzymatic reactions. However, solid proof of its clinical efficacy against cancer and the mechanism behind its effect have not been established. Moreover, cancer forms cancer-specific microenvironments and interacts with various cells, such as cancer-associated fibroblasts (CAFs), to maintain cancer growth and progression; however, the effect of ascorbic acid on the cancer microenvironment is unclear. This review discusses the effects and mechanisms of ascorbic acid on cancer, including the role of ascorbic acid concentration. In addition, we present future perspectives on the effects of ascorbic acid on cancer cells and the CAF microenvironment. Ascorbic acid has a variety of effects, which contributes to the complexity of these effects. Oral administration of ascorbic acid results in low blood concentrations (<0.2 mM) and acts as a cofactor for antioxidant effects, collagen secretion, and HIFα degradation. In contrast, intravenous treatment achieves large blood concentrations (>1 mM) and has oxidative-promoting actions that exert antitumor effects via reactive oxygen species. Therefore, intravenous administration at high concentrations is required to achieve the desired effects on cancer cells during treatment. Partial data on the effect of ascorbic acid on fibroblasts indicate that it may also modulate collagen secretion in CAFs and impart tumor-suppressive effects. Thus, future studies should verify the effect of ascorbic acid on CAFs. The findings of this review can be used to guide further research and clinical trials.

KEYWORDS
ascorbic acid, antitumor effect, cancer, cancer-associated fibroblast, antioxidant, intravenous administration
Introduction

Ascorbic acid, also known as vitamin C, is a low-molecular-weight compound with the chemical formula $C_6H_8O_6$ and a molecular weight of 176.12 g/mol. It is an essential water-soluble vitamin that cannot be synthesized in the human body (1). Instead, this vitamin must be acquired by consuming food. Inadequate provision of dietary vitamin C can lead to deficiencies such as scurvy (2–4). Ascorbic acid acts in vivo as an antioxidant and cofactor in various enzymatic reactions but also has attracted substantial attention for its potential antitumor effects (5, 6). However, the clinical efficacy of ascorbic acid as an anticancer treatment, and the mechanism behind its effects, have not yet been confirmed.

Cancer maintains its characteristic growth and progression by interacting with surrounding cells, forming a cancer microenvironment composed of various cells. Among these cells, cancer-associated fibroblasts (CAFs) play a significant role in cancer cell proliferation, invasion, and metastasis by providing growth factors and nutrients to cancer cells and reorganizing the extracellular matrix of the peri-cancer stroma (7–11). However, the effect of ascorbic acid on the cancer microenvironment is unclear. Moreover, the heterogeneity phenotype of fibroblasts in the peritumoral stroma of some carcinomas promotes tumor growth (12, 13). Therefore, elucidation of the heterogeneity of fibroblasts is urgently required for the effective destruction of cancer cells.

In this review, we discuss the differences between the antioxidant and oxidant-promoting effects of ascorbic acid, including the role of ascorbic acid concentration. Our current understanding of the concentration-dependent actions and processes of ascorbic acid is also explained. We then provide future perspectives on the antitumor effects of ascorbic acid on cancer cells and its effects on CAFs, which form a key cancer microenvironment.

Administration route and vascular concentration of ascorbic acid

Orally ingested ascorbic acid is absorbed by transporters of sodium-dependent vitamin C transporters (SVCTs) and glucose transporters (GLUTs) in the small intestine and excreted via the kidneys (14). In vivo, ascorbic acid exists as reduced ascorbic acid or oxidized ascorbic acid (dehydroascorbic acid (DHA)), which are respectively taken into cells through SVCTs and GLUTs (15–17). Rat experiments revealed variations between the oral and intravenous administration of ascorbic acid, whereby oral administration of 5 mg/g of body weight did not raise blood ascorbic acid concentrations, but intravenous administration of 5 mg/g boosted ascorbic acid concentrations to approximately 10 mM (18). However, since mice and rats can synthesize ascorbic acid in their bodies (<100 µM), it is necessary to be careful in applying the results of experiments with mice and rats to humans, whose systems cannot synthesize ascorbic acid. In human studies, oral administration of 400 mg or more of ascorbic acid maintained steady-state blood concentrations of 50–80 µM (19), with oral administration of 3 g of ascorbic acid every 4 h increasing the maximum blood concentration to approximately 220 µM. Conversely, intravenous administration of 50 g of ascorbic acid was predicted to increase the maximum blood concentration to approximately 13.4 mM (20). The half-life of ascorbic acid in the blood is 2.0 ± 0.6 h (21). Furthermore, in a report on patients with cancer, ascorbic acid concentrations in the blood reached 20.3–49.0 mM with intravenous administration of 60–70 g/m² or 1.5 g/kg of ascorbic acid (21–23). In other words, blood concentrations of ascorbic acid vary widely depending on the route of administration. Thus, the pharmacological effects of ascorbic acid resulting from the low concentrations achieved by oral administration (several hundred µM) may differ from those resulting from the high pharmacological concentrations achieved by intravenous administration (>1 mM). As such, the intended administration route of ascorbic acid must be considered. Adverse effects of ascorbic acid include effects on renal function and hemolysis caused by a deficiency of glucose-6-phosphate dehydrogenase (G6PD). Oral doses of more than 1000 mg per day increase renal excretion of urate and oxalate compared to lower doses, so caution should be exercised when administering high doses (19). G6PD is required for the proper function of glutathione peroxidase, especially in erythrocytes (24). However, many clinical trials in which high concentrations of intravenous ascorbic acid were administered as monotherapy or in combination with anticancer agents have shown no serious adverse effects (21, 25–27). Therefore, ascorbic acid is considered a drug with very low toxicity to the human body.

In vivo effects of ascorbic acid

Recent studies have demonstrated that ascorbic acid absorbed in vivo has both antioxidant and oxidant-promoting effects (28, 29). Ascorbic acid also exhibits various physiological effects by catalyzing Fe(II)- and 2-oxoglutarate-dependent dioxygenase reactions (14).

Ascorbic acid and reactive oxygen species

Ascorbic acid degrades reactive oxygen species (ROS) at average blood concentrations of 40–80 µM, reducing low-density lipoprotein oxidation associated with atherosclerosis and lipid oxidation of cell membranes (30–32). However, high pharmacological concentrations of ascorbic acid achieved via...
intravenous administration produce $H_2O_2$ in vivo (18, 33, 34) and then hydroxyl radicals via the Fenton reaction (35). Intravascularly, ROS produced by high concentrations of ascorbic acid are degraded by catalase in serum, whereas extravascularly, ROS accumulate without degradation by ascorbic acid and act as a pro-oxidant. Thus, ascorbic acid is notable for its paradoxical activity, serving as an antioxidant at low doses and a pro-oxidant at high doses (28, 29). In addition, oral administration of ascorbic acid does not reach the same pharmacological concentrations as intravenous treatment (19, 20); therefore, intravenous administration of ascorbic acid is required for pro-oxidant activity to occur. In a rat study, intravenous administration of 0.5 mg/g of ascorbic acid increased the $H_2O_2$ concentration in the extracellular fluid from undetectable to 20 $\mu$M, and intraperitoneal injection of the same dose increased $H_2O_2$ concentration to approximately 5 $\mu$M. In contrast, no increase in $H_2O_2$ concentration in the extracellular fluid was detected after oral administration of ascorbic acid (18). In addition, in a mouse subcutaneous transplantation model, intraperitoneal administration of 4 mg/g of ascorbic acid increased the $H_2O_2$ concentration in the extracellular fluid around the tumor to approximately 150 $\mu$M (34, 35).

Ascorbic acid as a cofactor for dioxygenase

Members of the Fe(II) and 2-oxoglutarate-dependent dioxygenase families catalyze many oxidation reactions throughout biology. Ascorbic acid acts as a coenzyme that catalyzes the reactions that produce hydroxylation products using 2-oxoglutarate and oxygen as substrates (36). Particularly well-known are the reactions in collagen (37) and HIF$\alpha$, which is a master regulator of the cellular hypoxia response pathway (38). The reaction in collagen is mediated by one of the proline hydroxylases, collagen prolyl-4-hydroxylase (C-P4H), which hydroxylates the procollagen proline (37). C-P4H has a high binding capacity to oxygen and is not affected by the oxygen concentration. Conversely, in the reactions in HIF$\alpha$, ascorbic acid catalyzes two types of reactions: PHD1-3 in proline hydroxylase (38–40) and factor inhibiting HIF-1 (FIH-1) in asparagine hydroxylase (41–43). In the PHD reaction, ascorbic acid degrades HIF$\alpha$ via ubiquitination by pVHL proteins (44–46). In the reaction of FIH-1, it suppresses the interaction with CBP/p300, which is a transcriptional cofactor, and suppresses the transcriptional activity of HIFs (42). These reactions are dependent on the oxygen concentration; thus, ascorbic acid acts as an oxygen sensor in the cell because the reaction is reduced in a hypoxic environment and HIF is not degraded (36). The concentrations of ascorbic acid necessary to sustain enzymatic activity of PHDs and FIH-1 are 140–180 $\mu$M and 260 $\mu$M, respectively (37) and are well above the steady-state blood concentrations of 40–80 $\mu$M, suggesting that these reactions require sufficient blood and tissue concentrations of ascorbic acid (14, 47). Ascorbic acid also acts as a cofactor for ten-eleven translocations (TETs) of DNA hydroxylases; TETs are proteins that convert 5-methylcytosine (mC) to 5-hydroxymethylcytosine (hmC) (48, 49). Ascorbic acid promotes DNA demethylation by accelerating the reaction of TETs (50).

Antitumor effect of ascorbic acid

Ascorbic acid exhibits antitumor effects in various carcinomas (5, 6, 51); however, clinical studies have not yet produced any significant evidence of these effects (52). Ascorbic acid exhibits antitumor effects through ROS-mediated mechanisms and as a cofactor. The mechanisms of ascorbic acid as a cofactor include effects on HIF$\alpha$ via PHDs and FIH-1 and epigenetic effects via DNA demethylases (6, 49). (Table 1) Ascorbic acid can also modulate metabolism and epigenetic gene expression in immune cells as well as cancer cells (64–67). Ascorbic acid is also known to inhibit EMT of tumor cells (58, 59). Here, we discuss the known antitumor effects of ascorbic acid.

ROS-mediated antitumor effects of ascorbic acid

The ROS-mediated mechanism is the most well-known mechanism of the antitumor effect of ascorbic acid in various carcinoma. Intravenous administration of high ascorbic acid concentrations acts as a pro-oxidant in vivo, producing ROS through the Fenton reaction (18). $H_2O_2$, a ROS formed outside of the cell, diffuses rapidly inside the cell (68) where it consumes antioxidants such as reduced glutathione and NADPH. In addition, in colorectal cancer with KRAS or BRAF mutations, lung cancer with KRAS mutations, and pancreatic cancer, GLUT1 expression is increased because of an accelerated glycolytic pathway, resulting in higher DHA absorption (69–72). ROS accumulation increases oxidative stress, such as DNA damage, and DNA damage increases PARP activity, thereby decreasing NAD$^+$ levels and limiting glycolytic system processes (73, 74). In addition, GAPDH, an enzyme of the glycolytic system, is inhibited in its enzymatic function by the reversible binding of oxidized glutathione to cystein152, which is reactive to oxidative stress (75). As a result, the glycolytic pathway produces less adenosine triphosphate (ATP), and cells suffer apoptosis. Indeed, in a report of metabolic changes induced by ascorbate in a colon cancer cell line with KRAS or BRAF mutations, metabolomic analysis using LC/MS/MS showed that upstream metabolites in the glycolytic reaction catalyzed by NAD$^+$ and GAPDH were accumulated, whereas downstream...
TABLE 1 The types and effects of Fe (II) and 2-oxoglutaric acid-dependent dioxygenases in which ascorbic acid acts as a cofactor.

| Effect | Collagen prolyl hydroxylases (C-P4H) | Proline hydroxylases | Factor inhibiting HIF-1α | DNA/histone demethylases (TETs/JHDMs) |
|--------|--------------------------------------|----------------------|--------------------------|--------------------------------------|
|        | Promotes collagen production by stabilizing the three-dimensional structure of procollagen through hydroxylation of its proline. | Degrade HIFα via ubiquitination by pVHL proteins. | Inhibits the transcriptional abilities of HIF1α via the interaction with CBP/p300. | Promote DNA demethylation and regulate epigenetic gene expression. |

Ascorbic acid concentration in previous reports: 100 μM (53–56) 25–1000 μM (36, 46, 57) 100–2000 μM (58–63)

Antitumor effects: Not clear. Inhibit tumor cell proliferation by inhibiting angiogenesis and suppressing the promotion of glycolysis. Reexpresses tumor suppressor genes and suppresses oncogenes. Prevent migration and metastasis by suppressing EMT of tumor cells.

C-P4H, collagen prolyl-4-hydroxylases; TETs, ten-eleven translocation enzymes; JHDMs, Jumonji-domain histone demethylases; HIF, hypoxia inducible factor α; pVHL protein, the von Hippel-Lindau protein; CBP, CREB-binding protein; EMT, epithelial-mesenchymal transition.

metabolites were reduced (74). Because of redox imbalance, cancer cells are susceptible to ROS and the effects of ascorbic acid (76). In conclusion, the pro-oxidant effect of high doses of ascorbic acid induces cell death by generating ROS in cancer cells and limiting ATP generation through the glycolytic pathway.

Conversely, the balance of oxidative stress and antioxidant activity plays a crucial role in tumor development and progression. In melanoma, ROS are overproduced by mitochondria or NADPH oxidase, which promotes tumor development and progression through DNA damage-induced mutation of oncogenes and signal transduction via NF-κB (77, 78). In addition, melanoma acquires metastatic potential due to enhanced production of antioxidant enzymes such as catalase and tolerance to oxidative stress (78, 79). Ascorbic acid has a dual impact on melanoma, with high concentrations triggering cell death and low amounts promoting tumor growth (80).

Despite the above reported antitumor effects of ascorbic acid at high concentrations, the ROS-mediated antitumor effects of ascorbic acid remain insufficent for the following reasons. First, the Fenton reaction-mediated ROS-generating effect of ascorbic acid, which is recognized in vitro, may be inhibited at in vivo concentrations of Fe²⁺ and Fe³⁺ (81). Second, in vivo, iron ions are always chelated, so the Fenton reaction may not occur (30). Finally, the inhibitory effect of ascorbic acid on ATP synthesis, even in the presence of PARP inhibitors in vitro, may be exerted by ascorbic acid regardless of the reduction of NAD⁺ levels by PARP (82). In conclusion, it is possible that in vitro results of the ROS-mediated antitumor effects of ascorbic acid are not compatible with its in vivo mode of action, suggesting that alternative anticancer mechanisms may be involved.

HIFα-mediated antitumor effects of ascorbic acid as a coenzyme

HIFα, which is expressed in many tumors such as melanoma, leukemia, and carcinomas, including colon, pancreatic, and lung cancer (83–87), is involved in angiogenesis and regulation of the glycolytic system, which are crucial processes for cancer growth and progression, suggesting that HIFα may be a novel cancer therapeutic strategy (88, 89). Ascorbic acid is a cofactor for Fe(II)- and 2-oxoglutarate-dependent dioxygenases and has various physiological effects, catalyzing the interaction of PHDs and FIH-1 and degrading the HIFα activity (44–46). Ascorbic acid concentrations in human tumor samples were negatively connected with HIF1α expression in colon cancer, with higher ascorbic acid concentrations associated with prolonged recurrence-free survival (83). In human endometrial tumors, patients with higher ascorbic acid levels in tumors had lower protein expression of HIF1α, VEGF, and GLUT1 and lower malignancy (90). In human pancreatic cancer cell lines, in vitro, low ascorbic acid concentrations (25 μM) reduced HIF1α expression and suppressed tumor growth under hypoxic conditions (57). In a model of subcutaneous lung tumor transplantation in rats, intraperitoneal injection of ascorbic acid (1 g/kg) suppressed HIF1α expression in tumors and decreased tumor growth and vascular density (91). In a mouse model of human B cell lymphoma implanted subcutaneously, oral treatment of ascorbic acid (5 g/L) reduced HIF1α expression and prevented tumor development (92).

Thus, the activity of ascorbic acid as a coenzyme may suppress HIFα expression and activity in tumor cells and may inhibit tumor cell proliferation by inhibiting angiogenesis.
Ascorbic acid regulates epigenomic modifications

Ascorbic acid catalyzes the reaction of DNA hydroxylase TETs and Jumonji C domain-containing histone demethylases (JHMDs), thereby having epigenetic antitumor effects (6, 49, 93). TET is a member of the same family of iron- and 2-oxoglutarate-dependent dioxygenases as PHDs, which convert 5-methylcytosine (5mC) into 5-hydroxymethylcytosine, promoting histone demethylation and contributing to oncogene suppression and the re-expression of tumor suppressor genes (94). In hematologic tumors such as acute myeloid leukemia and myelodysplastic syndromes, loss-of-function mutations in TET2 are known to occur frequently, resulting in decreased and hypermethylated 5hmC. In these hematologic tumors, administration of several hundred μM ascorbic acid has a gene reprogramming effect that restores TET function and increases 5hmC levels, suppressing cell proliferation and promoting myeloid progenitor cell differentiation (60, 94). In malignant melanoma, 5hmC is known to decrease as the disease progresses, and administration of 100 μM ascorbic acid restores 5hmC via TET, induces apoptosis in tumor cells, and shows antitumor effects (61, 62). For colon cancer, administration of 1 mM ascorbic acid has also been reported to increase 5hmC via TET in vitro, showing antitumor effects when combined with an inhibitor of isocitrate dehydrogenase (IDH) mutations (63). JHDMs are histone demethylases that use Fe2+ and α-ketoglutarate as cofactors to demethylate histones and regulate gene expression (95). Isocitrate dehydrogenases (IDH) mutations reduce α-ketoglutarate, a substrate for TETs and JHDMs, and promote DNA methylation in cells with IDH mutations, regulating gene expression that leads to carcinogenesis such as glioma (96). Ascorbic acid is necessary for the proper activity of JHDMs and may correct gene expression that promotes oncogenesis by promoting histone demethylation (93, 97). Essentially, ascorbic acid has antitumor effects by improving the hypermethylation state observed in tumors via TETs and JHDMs, and by reprogramming gene expression.

Ascorbic acid downregulates EMT

Ascorbic acid regulates the epithelial-mesenchymal transition (EMT), which is important for metastatic tumor potential. In vitro, ascorbic acid suppressed EMT in human pancreatic cancer cells by decreasing Snail and increasing E-cadherin at concentrations of 1-1.5 mM (98). Ascorbic acid, in conjunction with 5-azacytidine (5-AZA), a potent DNA methyltransferase inhibitor, regulated EMT inhibition and cell cycle progression in human HCC cells in vitro by suppressing Snail expression via TET (58). Interestingly, ascorbic acid produced two distinct reactions in human breast cancer in vitro. A low dose (100 μM) of ascorbic acid decreased E-cadherin and increased the mesenchymal marker vimentin, while a high dose (2 mM) of ascorbic acid conversely increased E-cadherin and decreased vimentin, reversing TGF-β1-induced EMT and, as a result, suppressing the formation of lung metastases in vivo (59). Ascorbic acid at concentrations of 1 mM or higher is thought to suppress EMT in tumors, possibly by inhibiting the effect of TGF-β1 or by regulating Snail expression by TETs.

Effects of ascorbic acid on fibroblasts

Ascorbic acid is known to enhance collagen synthesis (99, 100) and wound healing (101), reduce UV-induced damage (102, 103), and exhibit anti-inflammatory effects (104, 105); however, these effects are primarily skin-confined. Recently, the CAF cancer microenvironment has attracted considerable attention (10, 11), although few studies have described the effects of ascorbic acid on CAFs. Here, we describe the effects of ascorbic acid on fibroblasts.

Ascorbic acid and dermal fibroblasts

Ascorbic acid acts as a cofactor for C-P4Hs when taken up by human dermal fibroblasts and promotes collagen production by stabilizing the three-dimensional structure of procollagen through hydroxylation of its proline (4, 106, 107). In vitro, a low concentration of ascorbic acid (100 μM) in human skin fibroblasts increases the expression of type1,3,4 collagen and SVCT2 at the mRNA level (53-55) as well as increasing proliferation (56), suggesting a direct effect on fibroblasts. In human clinical data, oral ascorbic acid intake with exercise stimulation doubled the amino-terminal propeptide of collagen I in the blood, indicating enhanced collagen production (108). In addition, ascorbic acid concentrations as low as 0.17 mM in human skin fibroblasts increase the contractile phenotype of myofibroblasts in the presence of TGF-β1 through enhancement of the expression of TGFβ1-responsive genes, but do not increase such a phenotype in the absence of TGF-β1 (109). Ascorbic acid promotes collagen production and proliferation of skin fibroblasts as a coenzyme. Moreover, in these studies, ascorbic acid increases in collagen synthesis and secretion increased at concentrations as low as several hundred μM.
Ascorbic acid and other fibroblast reports

According to a study on tumor stroma, intraperitoneal administration of ascorbic acid at a high dose of 4 g/kg in an orthotopically transplanted mouse model of human pancreatic cancer resulted in tumor reduction, reduced metastasis, and enhanced tumor stroma due to increased collagen secretion (98). In the 4T1 breast cancer orthotopic model utilizing ascorbic acid-deficient (gulonolactone oxidase knockout mouse) mice, oral administration of ascorbic acid increased type 1 collagen to form a capsule around the tumor, and tumor boundaries were more clearly defined than in the control group (110). Thus, ascorbic acid may increase collagen production in the tumor stroma at both high and low doses. However, it is unknown whether this effect is on tumor cells or CAFs, and further research is needed to determine whether ascorbic acid activates CAFs in the tumor microenvironment and increases collagen production. In vitro, human hepatic stellate cells, which are responsible for liver fibrosis, were inhibited by low doses of ascorbic acid (50-200 M), which decreased intracellular TGF-1 in rat cell lines (111). In a report examining the development of pulmonary fibrosis by paraquat treatment, intraperitoneal administration of 150 mg/kg of ascorbic acid inhibited pulmonary fibrosis in a mouse model by inhibiting inflammatory cell infiltration into the bronchoalveolar lavage fluid, suppressing apoptosis by increasing antioxidant activity in the lung, and inhibiting TGF-β in the lung (112). As a result, ascorbic acid may inhibit fibrosis by inhibiting inflammatory cell infiltration and reduction of TGF-β in tissues. In our study, we also found that in vitro, human pancreatic-derived fibroblasts, whose proliferation is promoted when co-cultured with cancer cells, receive high doses (>1 mM) of ascorbic acid for growth inhibition. (Figure 1) In conclusion, the effects of low and high doses of ascorbic acid on CAFs, such as enhanced collagen production and inhibition of fibrosis development, differ from organ to organ or disease model to disease model and remain unclear.

Clinical trials on ascorbic acid

In the 1970s, clinical trials involving ascorbic acid revealed that a small sample of patients treated with intravenous and oral ascorbic acid lived longer than a control group (113, 114). At that time, the mechanism of the antitumor effect of ascorbic acid efficacy remained unclear, and subsequent randomized, double-blind, placebo-controlled trials with oral ascorbic acid failed to demonstrate a survival benefit (115, 116). Therefore, the antitumor effect of ascorbic acid was viewed unfavorably. Multiple mechanisms of ascorbic acid’s antitumor effect were subsequently proven in vitro, along with differences in ascorbic acid blood levels between oral and intravenous administration methods. Furthermore, the fact that blood levels of ascorbic acid...
were decreased in cancer patients (117, 118) and that the adverse effects associated with ascorbic acid administration were extremely low, led to the expectation that ascorbic acid could be used for therapeutic applications. (Table 2) There were a few scattered case reports showing tumor shrinkage with ascorbic acid treatment (131, 153–158), and there were also reports of antitumor effects in a small number of studies (25, 124, 159, 160). Ascorbic acid in combination with chemotherapeutic agents has also been researched, and some reports of reduced side effects and improved quality of life have been observed (21, 161, 162). In contrast, there have been no large-scale clinical trials that have demonstrated an additional antitumor effect by ascorbic acid (6, 76, 131, 163), and several ongoing clinical trials of ascorbic acid alone or in combination with chemotherapeutic agents for advanced colon cancer, pancreatic cancer, lung cancer, and other malignancies are expected to provide results in the near future (140, 148, 149, 151) (Table 2).

Discussion

Ascorbic acid is a medicine that has been widely investigated and used for a long time; however, its beneficial effects against cancer have not yet been proven by clinical trials. The contrasting in vivo effects of ascorbic acid may explain this. That is, the oxidative-promoting impact at high concentrations is detrimental to cancer cells, whereas the antioxidant effect at low concentrations may promote cancer (164). Because of this paradoxical effect, the administration route of ascorbic acid should be carefully considered. In addition, future research should explain the different activities of multiple dioxylases as cofactors, such as HIFα degradation, immune cell modulation, and epigenetic regulation of gene expression, in relation to the cancer microenvironment (Figure 2).

Additionally, research on the effects of ascorbic acid on CAFs implies the existence of novel therapeutic possibilities. Since the diversity of gene expression in fibroblasts in vivo differs among organs and pathological conditions (165), the effects of ascorbic acid on CAFs are also expected to vary among organs and pathological conditions. One of the potential effects of ascorbic acid may be the inhibition of tumor-promoting CAFs. Tumor-promoting CAFs support cancer growth by supplying cancer cells with nutrients and growth factors (7–11). Moreover, tumor-promoting CAFs control ECM secretion and protease secretion, remodel the ECM, and generate invasive routes necessary for solid tumor invasion (166, 167). Furthermore, in tumors with a high stromal component, such as pancreatic and breast cancer, the stromal fluid pressure in the tumor area increases, reducing drug delivery and indicating resistance to treatment (168, 169). Tumor-promoting CAFs promote cancer through cross-talk functions with cancer cells, ECM remodeling functions, and physical drug barrier functions. Ascorbic acid has an inhibitory effect on fibroblasts through a reduction in TGF at low doses and an inhibitory effect on cell proliferation via a

![FIGURE 2](image-url)

**FIGURE 2**

Overview of the various dose-dependent effects of ascorbic acid on cancer. ROS, reactive oxygen species; HIFα, hypoxia-inducible factor-alpha; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NAD⁺, nicotinamide adenine dinucleotide.
| Study* | Cancer types | Phase of study | Design of study | Therapy | Number of patients (with/without ascorbic acid) or estimated enrollment | Result or primary outcome measures (if trials are not reported) |
|--------|--------------|----------------|-----------------|---------|-------------------------------------------------------------------|-------------------------------------------------------------|
| NCT00954525 (25, 119) | pancreatic cancer | Phase I | single group assignment | Ascorbic acid (IV 50-100 g, 3 infusions per week), gemcitabine and erlotinib for 8 weeks per cycle | 9 | Seven patients were SD and 2 patients were PD. Time to progression was 89 days (standard deviation 77 days) and overall survival was 182 days (standard deviation 155 days) |
| NCT00006021 (120, 121) | multiple myeloma | Phase I/II | single group assignment | Ascorbic acid (IV 1 g, 5 infusions per week) and arsenic trioxide for 5 weeks per 7 week | 6 | Two patients were PR, and 4 patients were SD. |
| NCT00317811 (122, 123) | multiple myeloma | Phase II | single group assignment | Ascorbic acid (oral 1g, days 1-4 every 2 weeks), bortezomib and melphalan | 31 | Five patients were CR, 3 patients were VCPR, 6 patients were PR, 9 patients were MR, 6 patients were SD, and 2 patients were PD. |
| NCT01049880 (124, 125) | pancreatic cancer | Phase I | single group assignment | Ascorbic acid (IV 50-125 g, 2 infusions per week) and gemcitabine | 9 | Time to progression and overall survival were 26 ± 7 weeks and 13 ± 2 months. (Means ± SEM) |
| NCT01050621 (26, 126) | all cancer | Phase I/II | single group assignment | Ascorbic acid (IV 1.5 g/kg, 2 or 3 infusions per week) and chemotherapy | 14 | Three patients had unusually favorable experiences that were deemed highly unlikely to result from chemotherapy alone. |
| NCT01080352 (127, 128) | prostate cancer | Phase II | single group assignment | Ascorbic acid (IV week 1, 5 g; week 2, 30 g; and weeks 3–12, 60 g, once a week) | 23 | This treatment was not found to be effective. |
| NCT01364805 (98, 129) | pancreatic cancer | Phase I/IIa | single group assignment | Ascorbic acid (IV 75-100 g, 3 infusions per week) and gemcitabine | 14 | Median progression-free survival and median overall survival were 3 months and 15.1 months. |
| NCT00228319 (130, 131) | ovarian cancer | Phase I/IIa | parallel assignment, randomized | Arm 1: carboplatin and paclitaxel chemotherapy and ascorbic acid (IV 75-100 g, 2 infusion per week) for 6 months/Arm 2: carboplatin and paclitaxel chemotherapy | 25 (13/12) | There were no statistically significant difference in overall survival and the median time for disease progression/relapse. |
| NCT02655913 (132, 133) | non-small-cell lung cancer | Phase I/II | parallel assignment, randomized | Arm 1: administration of ascorbic acid (IV 1 g/kg, 3 infusions per week) for total 25 times, modulated electrohyperthermia, and supportive care/Arm 2: supportive care | 97 (49/48) | Progression-free survival (3 months vs. 1.85 months, P < 0.05) and overall survival (9.4 months vs. 5.6 months, P < 0.05) were significantly prolonged by combination therapy compared to BSC alone. Ascorbic acid may avoid standard 20-40% rates of severe toxicities. |
| NCT01905150 (134, 135) | pancreatic cancer | Phase II | parallel assignment, randomized | Arm 1: G-FLIP/G-FLIP-MD and ascorbic acid (IV 75-100 g, 2 infusions per week)/Arm 2: G-FLIP/G-FLIP-MD | 26 (we could confirm only abstract, and it did not describe details) | |

**Ongoing or unpublished clinical trials**

| Study* | Cancer types | Phase of study | Design of study | Therapy | Number of participants that experience serious adverse events. (Time Frame: 16 weeks +/- 2 weeks) | Disease control rate (CR+rPR+SD x18 weeks) (Time Frame: approximately 63 days) |
|--------|--------------|----------------|-----------------|---------|---------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| NCT01754987 (136) | hepatocellular carcinoma | Phase I/II | parallel assignment, randomized | Arm 1: ascorbic acid (IV 100 g, 3 infusions per week) for 16 weeks and sorafenib/Arm 2: sorafenib only | 5 (5/0) | Number of participants that experience serious adverse events. (Time Frame: 16 weeks +/- 2 weeks) |
| NCT03410030 (137) | pancreatic cancer | Phase Ib/II | single group assignment | Ascorbic acid (IV ≥20 mM), nab-paclitaxel, cisplatin, and gemcitabine | 36 | Disease control rate (CR+rPR+SD x18 weeks) (Time Frame: approximately 63 days) |

(Continued)
##TABLE 2 Continued

| Study* | Cancer types                                                                 | Phase of study | Design of study | Therapy                                                                 | Number of patients (with/without ascorbic acid) or estimated enrollment | Result or primary outcome measures (if trials are not reported) |
|--------|-------------------------------------------------------------------------------|----------------|----------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------|
| NCT03964688 (138) | multiple myeloma and lymphoma                                                   | Phase II       | parallel assignment, randomized | Arm 1: ascorbic acid (IV during hospitalization, after oral, total 6 weeks)/Arm 2: placebo | 47 | Immune recovery (Time Frame: day 14-28) |
| NCT02905578 (139) | pancreatic cancer                                                              | Phase II       | parallel assignment, randomized | Arm 1: ascorbic acid (IV 75 g, 3 infusions per week), gemcitabine, and nab-paclitaxel/Arm 2: gemcitabine and nab-paclitaxel | 65 | Overall survival (Time Frame: Every 2 months for up to 20 years post-treatment) |
| NCT03146962 (140) | colorectal, lung, and pancreatic cancer                                         | Phase II       | single group assignment | Cohort A: ascorbic acid (IV 1.25 g/kg, 4 infusions per week) for 2-4 consecutive weeks/Cohort B: ascorbic acid (IV 1.25 g/kg, 4 infusions per week) up to 6 months/Cohort C: ascorbic acid (IV 1.25 g/kg, 4 infusions per week) for 1-3 weeks and Yttrium-90 radioembolization of hepatic metastases | 78 | Change in antitumor activity measured by pathologic response based on tumor regression grading in cohort A patients. (Time Frame: cohort A - 8 weeks) Three-month disease control rate will be evaluated using RECIST v 1.1 in cohort B patients. (Time Frame: Cohort B - 3 months) Maximal tolerated dose of high dose vitamin C in combination with Y90 radioembolization (Time Frame: Cohort C - 16 weeks) |
| NCT03418038 (141) | high grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements, recurrent diffuse large B-cell lymphoma, recurrent Hodgkin lymphoma, recurrent lymphoma, refractory diffuse large B-cell lymphoma, and refractory lymphoma | Phase II       | parallel assignment, randomized | Arm A: ascorbic acid (IV) on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and combination chemotherapy./Arm B: placebo (normal saline) (IV) on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and combination chemotherapy./Arm C: ascorbic acid (IV) on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and another combination chemotherapy from Arm A and B. | 147 | Overall response rate (Arms A and B) (Time Frame: Up to 2 years) Overall response rate (Arm C) (Time Frame: Up to 2 years) |
| NCT03433781 (142) | myelodysplastic syndromes                                                       | Phase Ib/II    | single group assignment | Ascorbic acid (continuous intravenous infusion/24 hours 50 g, 5 infusions every 4 week) | 18 | Measure of serum bioavailability of ascorbic acid in Myelodysplastic syndrome patients with ten-eleven translocation 2 mutations (Time Frame: 6 Months) |
| NCT03508726 (143) | soft tissue sarcoma                                                             | Phase II       | single group assignment | Ascorbic acid (IV 62.5 or 75 g, 3 infusions per week) | 25 | Tumor response as assessed by pCR rate (Time Frame: Start of treatment up to 6 weeks after the last ascorbate infusion) |
| NCT03682029 (144) | myelodysplastic syndromes, chronic myelomonocytic leukemia-1, and cytopenia    | Phase I/II     | parallel assignment, randomized | Arm 1: ascorbic acid (oral 1000 mg, daily) for 12 months/Arm 2: placebo | 100 | Median change from baseline in variant allele frequency at 12 months (Time Frame: At baseline and at 12 months) |
| NCT03799094 (145) | non-small-cell lung cancer                                                      | Phase I/II     | parallel assignment, randomized | Arm 1: ascorbic acid (IV 30 g, once a week) and daily taking tyrosine kinase inhibitor/Arm 2: daily taking tyrosine kinase inhibitor | 150 | Progression free survival (Time Frame: From the start date of treatment until the date of first documented progression or death, assessed up to 2 years) |
| NCT03999723 (146) | myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia | Phase II       | parallel assignment, randomized | Arm 1: ascorbic acid (oral 1000 mg, daily) and azathioprine/Arm 2: placebo and azathioprine | 196 | Event-free survival (Time Frame: 0-34 months) |

(Continued)
prooxidant effect at higher doses, suggesting that it may have an inhibitory effect on tumor-promoting CAFs.

Conversely, collagen is known to form a barrier that physically obstructs cell migration without protease degradation (170, 171). In a mouse model lacking -SMA-positive fibroblasts, the tumor suppressive effects of CAFs have been demonstrated to induce an undifferentiated tumor phenotype and dramatically reduce survival (172). The increase in cancer stroma, tumor shrinkage, and metastasis inhibition effects of ascorbic acid may be attributed to the activation of tumor suppressive fibroblasts and the formation of collagen barriers that inhibit tumor progression.

Ascorbic acid may also affect CAFs via suppression of HIF1α. Tumor-induced ROS-mediated "pseudo-hypoxia" in CAFs leads to the accumulation of HIF1α and enhanced aerobic glycolysis (173, 174). Furthermore, high expression of HIF1α in CAFs induces protein expression in myofibroblasts in CAFs, and inhibition or knockout of HIF1α improves their phenotype (175). Stimulation by TGF-β or PDGF also suppresses IDH3 expression and decreases 2-oxoglutarate in fibroblasts, resulting in HIF1α accumulation and regulating fibroblast differentiation into CAFs (176). Ascorbic acid may inhibit the accumulation of HIF1α by promoting the reaction of 2-oxoglutarate-dependent dioxygenases such as PHDs and FIH-1, thereby suppressing fibroblast differentiation into CAFs. The JAK1/STAT3 pathway is also an important pathway that maintains actomyosin contractility and the CAF phenotype (177), and methylation of the promoter of protein tyrosine phosphatase non-receptor type 6 (SHP-1), which negatively regulates the JAK/STAT pathway, allowing for sustained signaling (167). For this epigenetic reorganization, DNA demethylase-mediated effects such as TETs of ascorbic acid may be exerted. However, CAFs have an enhanced glycolytic system due to chronic hypoxia in the tumor microenvironment and subsequent epigenetic reorganization by demethylation of HIF1α and promoters of enzymes of the glycolytic system (178),

### TABLE 2 Continued

| Study* | Cancer types | Phase of study | Design of study | Therapy | Number of patients (with/without ascorbic acid) or estimated enrollment | Result or primary outcome measures (if trials are not reported) |
|--------|--------------|----------------|----------------|---------|-------------------------------------------------|----------------------------------------------------------|
| NCT04033107 (147) | hepatocellular cancer, pancreatic cancer, gastric cancer, and colorectal cancer | Phase II | single group assignment | Ascorbic acid (IV 1.5 g/kg, D1-3, every 2 weeks) and metformin | 30 | Progression-free survival (Time Frame: up to 12 weeks) |
| NCT04046094 (148) | bladder cancer | Phase I/II | single group assignment | Ascorbic acid (IV 25 g, 2 infusions per week) for 4 weeks | 21 | Post treatment pathological staging (Time Frame: 10 weeks) |
| NCT04516681 (149) | colorectal cancer | Phase III | parallel assignment, randomized | Arm 1: ascorbic acid (IV 1.5g/kg/day, D1-3, every 2 weeks) and FOLFOXIRI+/- bevacizumab/Arm 2: FOLFOXIRI+/- bevacizumab | 400 | Objective response rate (Time Frame: up to 5 years) |
| NCT04634227 (150) | sarcoma, soft tissue sarcoma, unresectable soft tissue sarcoma, metastatic bone tumor, and bone sarcoma | Early Phase I | single group assignment | Ascorbic acid (IV 20-30 mM) on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle, and gemcitabine | 20 | Determine the 12 weeks progression free survival at 12 weeks post treatment initiation (Time Frame: 12 weeks post-treatment) |
| NCT04801511 (151) | rectal cancer | Phase II | single group assignment | Ascorbic acid (IV 24 g, 25 times) with preoperative concurrent intensity-modulated radiation therapy and mFOLFOX6 chemotherapy, and then preoperative mFOLFOX6 chemotherapy | 60 | pCR rate (Time Frame: 2 year From the first subject underwent surgery to the last subject underwent surgery.) |
| NCT02516670 (152) | prostate cancer | Phase II | parallel assignment, randomized | Arm 1: ascorbic acid (IV 25 g, 2 infusions per week) for 3 weeks and docetaxel/Arm 2: placebo and docetaxel | 50 | Terminated (insufficient clinical response per DSMB) |

*This table describes clinical trials since 2000. IV, intravenous injection; CR, complete response; VGPR, very good partial response; PR, partial response; SD, stable disease; PD, progressive; pCR, pathologic complete response; DSMB, Data and Safety Monitoring Board.
and there may be unexpected epigenetic effects of ascorbic acid that should be clarified in the future. Ascorbic acid may have a tumor suppressive effect by affecting CAFs and reprogramming them into normal fibroblasts. (Figure 3) It is possible that the antitumor effect of ascorbic acid can be improved by examining the method of administration and adapting it to the expression status of HIF in tumors and CAFs. Furthermore, elucidating the effects of ascorbic acid targeting not only tumor cells but also tumor microenvironments such as CAFs may help to reveal further antitumor effects of ascorbic acid.

Acknowledgments

The authors would like to thank Ikuko Arikawa, Yumiko Ito, and Sachiko Sawada for technical assistance with the experiments. Furthermore, we would like to thank Editage (www.editage.jp) for English language editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

1. Nishikimi M, Koshiba T, Ozawa T, Yagi K. Occurrence in humans and guinea pigs of the gene related to their missing enzyme l-gulono-gamma-lactone oxidase. Arch Biochem Biophys (1988) 267:842–6. doi: 10.1016/0003-9861(88)90053-8.

2. Valdes E. Vitamin C. Actas Dermo Sifiliogr (2006) 97:557–68. doi: 10.1111/1116-1246

3. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee HJ, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr (2003) 22:118–35. doi: 10.1080/073157203.10719272.

4. Peterkofsky B. Ascorbate requirement for hydroxylation and secretion of procollagen: relationship to inhibition of collagen synthesis in scurvy. Am J Clin Nutr (1991) 54:1135S–40. doi: 10.3945/ajcn.1991.54.4.1135S.

5. Villagra M, Ferreira J, Martorell M, Maridones L. The role of vitamin C in cancer prevention and therapy: A literature review. Antioxid (Basel) (2021) 10.1093/ajcn/74.3.402. doi: 10.1038/417t77.

6. Souza CM, Biancar DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine transport. Cancer Res (2021) 80:3628–40. doi: 10.1158/0008-5472.CAN-20-2686.

7. Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature (2016) 536:479–83. doi: 10.1038/nature19084.

8. Parker SJ, Amendola CR, Hollinshead KER, Yu Q, Yamamoto K, Encarnacion-Rosado J, et al. Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic cancer. Cancer Discov (2020) 10:1818–37. doi: 10.1158/2159-8290.CD-19-0595.

9. Ikuta D, Miyake T, Shimizu T, Sonoda H, Mukaisho KI, Tokuda A, et al. Fibrosis in metastatic lymph nodes is clinically correlated to poor prognosis in colorectal cancer. Oncotarget (2018) 9:29574–86. doi: 10.18632/oncotarget.25636.

10. Sahai E, Astaturor I, Cukierman E, DeNardo DG, Egelblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer (2020) 20:174–86. doi: 10.1038/s41561-019-0323-8.

11. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer (2006) 6:392–401. doi: 10.1038/nrc1877.

12. Maehira H, Miyake T, Iida H, Tokuda A, Mori H, Yasukawa D, et al. Vimentin expression in tumor microenvironment predicts survival in pancreatic ductal adenocarcinoma: heterogeneity in the Vimentin expression in tumor microenvironment predicts survival in pancreatic ductal adenocarcinoma: heterogeneity in the Vimentin. Cancer Discov (2016) 22:18

13. Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, et al. Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res (1999) 59:5367–81. doi: 10.1158/0008-5472.CAN-99-0454.

14. Padayatty SJ, Levine M. Vitamin C physiology: the known and the unknown. Nutr Rev (2020) 78:53–67. doi: 10.1093/nutrev/nbaa086.

15. Muratani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, et al. Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res (1999) 59:5367–81. doi: 10.1158/0008-5472.CAN-99-0454.

16. Wang Y, Mackenzie B, Tsukaguchi H, Weremowicz S, Morton CC, Hediger MA, et al. Human vitamin C (l-ascorbic acid) transporter SVCT1. Biochim Biophys Acta Rev Commun (2000) 267:488–94. doi: 10.1016/S0968-1904(99)19929.

17. Muñoz-Montesino C, Petha E, Roa FJ, Somotayor K, Escobar E, Rivas CJ. Transport of vitamin C in cancer. Antioxid Redox Signal (2011) 35:61–74. doi: 10.1089/ars.2010.8166.

18. Chen Q, Espy MG, Sun AY, Lee HJ, Krishna MC, Shacter E, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA (2007) 104:8749–54. doi: 10.1073/pnas.0702854104.

19. Levine M, Cour-Cantinelle C, Wang Y, Welch RW, Washko PW, Dharwal KR, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA (1996) 93:370–9. doi: 10.1073/pnas.93.8.370.

20. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med (2004) 140:533–7. doi: 10.1093/anntrans/81.4.489.1-7.20040460-00010.

21. Stephenson CM, Levin RD, Specter T, Lis CG. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol (2013) 72:1239–46. doi: 10.1007/s00280-013-2179-9.

22. Nielsen TK, Høeggaard M, Andersen JT, Poulsen HE, Lykkefeldt J, Møllegaard K. ELIMINATION OF ASCORBIC ACID AFTER HIGH-DOSE INFUSION IN PROSTATE CANCER (2013) 116:343–8. doi: 10.1111/jcp.12323.
1. Regulatory prohydrolases. *Science* (2001) 292:468–72. doi: 10.1126/
 2. Cocksack ME, Masson N, Mole DR, Jaaskola P, Chang GW, Clifford SC, et al. Hypoxia inducible factor-alpha binding and ubiquitination by the von hippel-
 3. Riemer C, Dachs GU, Currie MJ, Vissers MC. Intracellular ascorbate enhances hypoxia-inducible factor (HIF)-hydrolase activity and preferentially suppresses the HIF-1 transcriptional response. *Free Radic Biol Med* (2014) 69:308–
 4. Lykkefeldt J, Tveden-Nyborg P. The pharmacokinetics of vitamin c. *Nutrients* (2019) 11:2412. doi:10.3390/nutrients11102412
 5. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science* (2009) 324:930–5. doi:10.1126/science.1170116
 6. Camarena V, Wang G. The epigenetic role of vitamin c in health and disease. *Cell Mol Life Sci* (2016) 73:1645–58. doi:10.1007/s00018-016-2145-x
 7. Blaschke K, Ebata KT, Karimi MM, Zepeda-Martinez JAY, Gao P, Mahapatra S, et al. Vitamin c induces tet-dependent DNA demethylation and a blastocyst-like state in ES cells. *Nature* (2013) 500:222–6. doi:10.1038/nature12362
 8. Hamaguchi R, Ito T, Narui R, Morikawa H, Uemoto S, Wada H. Effects of ascorbic acid encapsulated into negatively charged liposomes on collagen gene transcription in human skin fibroblasts. *Biochem Biophys Res Commun* (2013) 430:579–
 9. Tajima S, Pinnell SR. Ascorbic acid preferentially enhances type I and III collagen gene transcription in human skin fibroblasts. *J Dermatol Sci* (2001) 22:273–80. doi:10.1016/S0923-1847(01)00136-8
 10. van Gorkom GNY, Lookermans EL, Van Elssen CHMJ, Bos GMJ. The effect of vitamin c on in vitro human scalp fibroblasts. *Biochem Biophys Res Commun* (2019) 500:222–6. doi:10.1016/j.bbrc.2018.11.1909B in malignant melanoma cells. *Am J Physiol Cell Physiol* (2001) 280:C659–76. doi:10.1152/ajpcell.2000.280.6.C659
 11. Yang J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. *Science* (2009) 325:1555–9. doi:10.1126/science.1174229
 12. Sasaki H, Shitara M, Yokota K, Hikosaka Y, Moriyama S, Yano M, et al. Overexpression of GLUT1 correlates with kras mutations in lung carcinomas. *Mol Med Rep* (2012) 5:599–602. doi:10.3892/mmr.2011.736
 13. Bryant KL, Mancins JD, Kimmelman AC, Der CJ. KRAS: fueling pancreatic cancer proliferation. *Trends Biochem Sci* (2014) 39:91–108. doi: 10.1016/j.tibs.2013.12.004
 14. Alano CC, Garner P, Ying W, Higashi Y, Kauppinen TM, Swanson RA. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. *J Neurosci* (2010) 30:2967–78. doi:10.1523/
 15. Hwang NR, Yin SM, Kim YM, Jeong J, Song EJ, Lee Y, et al. Oxidative modification of glycerylaldehyde 3-phosphate dehydrogenase play a key role in its multiple cellular functions. *Biochem J* (2009) 423:253–64. doi:10.1042/BJ20090854
 16. Ngo B, Van Riper JM, Cantley LC, Yung J. Targeting cancer vulnerabilities with high-dose vitamin c. *Nat Rev Cancer* (2019) 19:271–82. doi:10.1038/s41561-019-0135-7
 17. Brar SS, Kennedy TP, Whorton AR, Sturrock AB, Huecksteadt TP, Ghio AJ, et al. Reactive oxygen species from NAD(P)H:quinone oxidoreductase constitutively activate NF-kappaB in malignant melanoma cells. *Am J Physiol Cell Physiol* (2001) 280:C659–76. doi:10.1152/ajpcell.2000.280.6.C659
 18. Sagval SK, Bekeschus S. ROS pleiotropy in melanoma and local therapy with physical modalities. *Oxid Med Cell Longev* (2021) 2021:6816214. doi: 10.1155/2021/6816214
 19. Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, et al. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. *Cancer Res* (2005) 65:1375–8. doi:10.1158/0008-5472.CAN-04-0631
 20. Yang G, Yang Y, Ma Y, Yang Y. Vitamin c at high concentrations induces cytotoxicity in malignant melanoma but promotes tumor growth at low concentrations. *Mol Cancer* (2017) 16:5965–76. doi:10.1007/s12032
 21. Murayama Y, Kashiyagura R, Ohnishi E, Ishida Y, Shinada T, Satoh T, Fe2+ as a physiological and selective inhibitor of vitamin c-induced cancer cell death. *Oxidant React Specie* (2020) 10:180–96. doi:10.2147/oro.2020.833
 22. Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. *Clin Cancer Res* (2016) 16:509–20. doi:10.1158/1078-0432.CCR-15-3061
 23. Kuiper C, Dachs GU, Munn D, Currie MJ, Robinson BA, Pearson JF, et al. Increased tumor ascorbate is associated with extended disease-free survival and decreased hypoxia-inducible factor-1 activation in human colorectal cancer. *Front Oncol* (2014) 4:10. doi:10.3389/fonc.2014.00010
 24. Ding DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F, et al. Hypoxia-inducible factor-1A promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. *Cancer Res* (2006) 66:6684–693. doi:10.1158/0008-5472.CAN-05-2887
 25. Shukla SK, Purahot V, Mehta K, Gunda V, Chaika NV, Vernucci E, et al. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. *Cancer Cell* (2017) 32:1–87.e7. doi:10.1016/j.ccr.2017.06.004
 26. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. *Clin Cancer Res* (2012) 18:1696–73. doi:10.1158/1078-0432.CCR-11-1909B in malignant melanoma cells. *Am J Physiol Cell Physiol* (2001) 280:C659–76. doi:10.1152/ajpcell.2000.280.6.C659
 27. Gerecke C, Schumacher F, Berndzen A, Homann T, Kleuser B. Vitamin c in inflammation and cancer. *Front Oncol* (2014) 4:207. doi:10.3389/fonc.2014.00207
 28. Sajadian SO, Tripathi C, Samani FS, Ruoss M, Dooley S, Baharvand H, et al. Vitamin c enhances epigenetic modifications induced by 5-azacytidine and cell cycle arrest in the hepatocellular carcinoma cell lines HLE and Huh7. *Clin Epigenet* (2016) 8:46. doi:10.1186/s13148-016-0213-6
 29. Zeng LH, Wang QM, Feng LY, Ke XD, Xu QZ, Wei AY, et al. High-dose vitamin c suppresses the HIF-1 transcriptional response. *Oncol Targets Ther* (2012) 7:6405–13. doi:10.2147/OTT.S227922
 30. Mingay M, Chaturvedi A, Bilenky M, Cao Q, Jackson L, Hui T, et al. Vitamin c selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. *Cancer Cell* (2017) 32:1–87.e7. doi:10.1016/j.ccr.2017.06.004
 31. Jun X, Dai L, Ma Y, Wang J, Liu Z. Implications of HIF-1α in the tumorigenesis and progression of pancreatic cancer. *Cancer Cell Int* (2020) 20:273. doi:10.1186/s12935-020-0137-0
Maekawa et al. 10.3389/fonc.2022.981547

Materials

bmc-2014-0010

Sci Rep

parenteral ascorbate inhibited pancreatic cancer growth and metastasis: vitamin C on rat hepatic stellate cells. induced by paraquat.

vitamin C.

solid tumours of ascorbate-dependent mice.

Ascorbic acid promotes a TGF-β-induced myo

microsomal polypeptide leading to formation of collagen.

Proc Natl Acad Sci

j.1524-4725.2005.31725

other dermatologic conditions.

suppresses TNF alpha-induced NF-kappaB activation by inhibiting I kappa b.

1996) 106:1086

105. Pinnell SR. Regulation of collagen biosynthesis by ascorbic acid: a review. Yale J Biol Med (1998) 58:553-9

106. Peterkofsky B, Udenfriend S. Enzymatic hydroxylation of proline in proline-rich proteins. Proc Natl Acad Sci

107. Pinnell SR. Regulation of collagen biosynthesis by ascorbic acid: a review. Yale J Biol Med (1998) 58:553-9

108. Shaw G, Lee-Barthel C, Ross ML, Wang B, Baar K. Vitamin C-enriched gelatin supplementation before intermittent exercise augments collagen synthesis. Am J Clin Nutr (2017) 105:136–43. doi: 10.3945/ajcn.116.138594

109. Piersma B, Wouters OY, de Rond S, Boersma M, Gijtema RAF, Bank RA. Ascorbic acid protects a TGFβ1-induced myofibroblast phenotype switch. Physiol Rep (2017) 5:e13324. doi: 10.1484/PJR.13324

110. Cha J, Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Cameron GS, Pence BC. Antioxidant nutrients protect against radiation-induced myelosuppression. Nutrients (2020) 12:1855:144. doi: 10.3390/nu12074833

111. Cha J, Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Cameron GS, Pence BC. Antioxidant nutrients protect against radiation-induced myelosuppression. Nutrients (2020) 12:1855:144. doi: 10.3390/nu12074833

112. Fong DW, Wang K, Jiang H, Li W, Qiang M, Dong T, Li H. Role of vitamin C in skin aging. Int J Cosmet Sci (2017) 39:363–70. doi: 10.1111/ijcs.12539

113. Polireddy K, Dong R, Reed G, Yu J, Chen P, Williamson S, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. a controlled trial. N Engl J Med (1993) 329:101–6. doi: 10.1056/NEJM199802273101303

114. Moertel CG, Fleming TR, Creagan ET, O’Fallon JR, Schutt AH, O’Connell MJ, Rubin J, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. a controlled trial. N Engl J Med (1979) 301:687–90. doi: 10.1056/NEJM198007301010917

115. Storkson J, Higman CE, Li K, Wu X, Wang W, et al. A research trial of high dose vitamin C and chemotherapy for metastatic pancreatic cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT00954525 [Accessed August 15, 2022]

116. ClinicalTrials.gov Identifier: NCT00954525. Intravenous vitamin C in combination with standard chemotherapy for pancreatic cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT00954525 [Accessed August 15, 2022]

117. Carr AG, Spencer E, Das A, Meijer N, Lauren C, MacPherson S, et al. Patients undergoing myeloablative chemotherapy and hematopoietic stem cell transplantation exhibit depleted vitamin C status in association with febrile neutropenia. Nutrients (2020) 12:1857:149. doi: 10.3390/nu12061879

118. Mayland CR, Bennett MJ, Allan K. Vitamin C deficiency in cancer patients. Palliat Med (2005) 19:17–20. doi: 10.1177/02699806050090790a

119. ClinicalTrials.gov Identifier: NCT00317811. Bortezomib, ascorbic acid, and melphalan in treating patients with newly diagnosed multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT00317811 [Accessed August 15, 2022]

120. Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Eur J Haematol (2009) 82:433–9. doi: 10.1111/j.1600-0690.2009.01244.x

121. Walsh LA, Fang F, Yilmaz E, et al. IDH1 and IDH2 mutations in human breast cancer. Cancer Res (2007) 67:7547–53. doi: 10.1158/0008-5472.CAN-07-0332

122. ClinicalTrials.gov Identifier: NCT00948890. A research trial of high dose vitamin C and chemotherapy for metastatic pancreatic cancer. (2015). Available at: https://clinicaltrials.gov/ct2/show/NCT00948890 [Accessed August 15, 2022]

123. Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Eur J Haematol (2009) 82:433–9. doi: 10.1111/j.1600-0690.2009.01244.x

124. Welsh JL, Wagner BA, van’t Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol (2013) 71:765–75. doi: 10.1007/s00280-013-2070-8

125. ClinicalTrials.gov Identifier: NCT01049880. A research trial of high dose vitamin C and chemotherapy for metastatic pancreatic cancer. (2015). Available at: https://clinicaltrials.gov/ct2/show/NCT01049880 [Accessed August 15, 2022]

126. ClinicalTrials.gov Identifier: NCT01050621. Trial of chemotherapy plus intravenous vitamin C in patients with advanced cancer for whom chemotherapy alone is only marginally effective. (2010). Available at: https://clinicaltrials.gov/ct2/show/ NCT01050621 [Accessed August 15, 2022]

127. ClinicalTrials.gov Identifier: NCT01080352. Vitamin C as an anti-cancer drug. (2010). Available at: https://clinicaltrials.gov/ct2/show/ NCT01080352 [Accessed August 15, 2022]

128. Nielsen TK, Hoigard M, Andersen JT, Jørgensen NR, Zerahn B, Kristensen B, et al. Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial. Transl Androl Urol (2017) 6:517–28. doi: 10.21037/tau.2017.04.42

129. ClinicalTrials.gov Identifier: NCT01364805. New treatment option for pancreatic cancer. (2011). Available at: https://clinicaltrials.gov/ct2/show/NCT01364805 [Accessed August 15, 2022]

130. ClinicalTrials.gov Identifier: NCT00228319. Treatment of newly diagnosed ovarian cancer with antioxidants. (2005). Available at: https://clinicaltrials.gov/ct2/show/ NCT00228319 [Accessed August 15, 2022]

131. Ma Y, Chapman J, Levine M, Poliroyder K, Drisko J, Chen Q. High-dose parental ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med (2014) 6:222ra18. doi: 10.1126/ scitranslmed.3007154

132. ClinicalTrials.gov Identifier: NCT00265913. Safety and efficacy of vitamin c infusion in combination with local mSHT to treat non small cell lung cancer. (2016). Available at: https://clinicaltrials.gov/ct2/show/NCT00265913 [Accessed August 15, 2022]

133. Ou J, Zhu X, Chen P, Du Y, Lu Y, Peng X, et al. A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer. J Adv Res (2020) 24:175–82. doi: 10.1016/j.jare.2020.03.004
Maekawa et al. 10.3389/fonc.2022.981547

ASCORBIC ACID IN TREATING PATIENTS WITH METASTATIC PROSTATE CANCER. (2022). Available at: https://clinicaltrials.gov/ct2/show/NCT02516670 [Accessed August 15, 2022].

ASCORBIC ACID AND INDUCTION CHEMOTHERAPY FOR HIGH-RISK Prostate CANCER. J Clin Oncol (2017) 35:15. suppl:A15711. doi: 10.1200/JCO.2017.35:15.suppA15711

ASCORBIC ACID IN THE TREATMENT OF LIVER CANCER TO DETERMINE IF IT IS SAFE AND EFFECTIVE. (2012). Available at: https://clinicaltrials.gov/ct2/show/NCT01754987 [Accessed August 15, 2022].

ASCORBIC ACID IN THE TREATMENT OF METASTATIC PROSTATE CANCER. (2013). Available at: https://clinicaltrials.gov/ct2/show/NCT01905150 [Accessed August 15, 2022].

ASCORBIC ACID WITH CHEMOTHERAPY AS A REPORT ON CANCER IMMUNOTHERAPY. (2019). Available at: https://clinicaltrials.gov/ct2/show/NCT03682029 [Accessed August 15, 2022].

ASCORBIC ACID AND ANTIMETASTATIC ACTIVITY. (2018). Available at: https://clinicaltrials.gov/ct2/show/NCT03999723 [Accessed August 15, 2022].

ASCORBIC ACID WITH CHEMOTHERAPY AND IMMUNOTHERAPY AS A REPORT ON CANCER IMMUNOTHERAPY. (2019). Available at: https://clinicaltrials.gov/ct2/show/NCT0433781 [Accessed August 15, 2022].

ASCORBIC ACID IN THE TREATMENT OF METASTATIC PROSTATE CANCER. (2012). Available at: https://clinicaltrials.gov/ct2/show/NCT03410030 [Accessed August 15, 2022].

ASCORBIC ACID IN THE TREATMENT OF METASTATIC PROSTATE CANCER: TWO CASES. (2019). Available at: https://clinicaltrials.gov/ct2/show/NCT03682029 [Accessed August 15, 2022].

ASCORBIC ACID AND IMMUNOTHERAPY AS A REPORT ON CANCER IMMUNOTHERAPY. (2018). Available at: https://clinicaltrials.gov/ct2/show/NCT03508726 [Accessed August 15, 2022].

ASCORBIC ACID FOR THE TREATMENT OF METASTATIC PROSTATE CANCER: THREE CASES. (2020). Available at: https://clinicaltrials.gov/ct2/show/NCT03996688 [Accessed August 15, 2022].

ASCORBIC ACID IN TREATING PATIENTS WITH METASTATIC PROSTATE CANCER: THREE CASES. (2017) 35(15_suppl):e15711. doi:10.1200/JCO.2017.35.15_suppl.e15711

ASCORBIC ACID IN TREATING PATIENTS WITH METASTATIC PROSTATE CANCER: A SYSTEMATIC REVIEW. (2019) 35:11. doi: 10.3389/imed.2019.00111

ASCORBIC ACID IN TREATING PATIENTS WITH METASTATIC PROSTATE CANCER. (2019). Available at: https://clinicaltrials.gov/ct2/show/NCT02905578 [Accessed August 15, 2022].

ASCORBIC ACID IN TREATING PATIENTS WITH METASTATIC PROSTATE CANCER. (2013). Available at: https://clinicaltrials.gov/ct2/show/NCT02905578 [Accessed August 15, 2022].

ASCORBIC ACID IN TREATING PATIENTS WITH METASTATIC PROSTATE CANCER: A REPORT ON CANCER IMMUNOTHERAPY. (2019). Available at: https://clinicaltrials.gov/ct2/show/NCT03146962 [Accessed August 15, 2022].

ASCORBIC ACID AND COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA. (2016). Available at: https://clinicaltrials.gov/ct2/show/NCT03410030 [Accessed August 15, 2022].

ASCORBIC ACID AND INDUCTION CHEMOTHERAPY FOR HIGH-RISK Prostate CANCER. J Clin Oncol (2017) 35:15. suppl:A15711. doi: 10.1200/JCO.2017.35:15.suppA15711

ASCORBIC ACID IN TREATING PATIENTS WITH METASTATIC PROSTATE CANCER: A REPORT ON CANCER IMMUNOTHERAPY. (2018). Available at: https://clinicaltrials.gov/ct2/show/NCT03410030 [Accessed August 15, 2022].

ASCORBIC ACID IN TREATING PATIENTS WITH METASTATIC PROSTATE CANCER: A REPORT ON CANCER IMMUNOTHERAPY. (2018). Available at: https://clinicaltrials.gov/ct2/show/NCT03969904 [Accessed August 15, 2022].

ASCORBIC ACID AND COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF METASTATIC PROSTATE CANCER. (2020). Available at: https://clinicaltrials.gov/ct2/show/NCT03058076 [Accessed August 15, 2022].

ASCORBIC ACID WITH CHEMOTHERAPY FOR EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS. (2019). Available at: https://clinicaltrials.gov/ct2/show/NCT03999723 [Accessed August 15, 2022].

ASCORBIC ACID AND THERAPY FOR METASTATIC PROSTATE CANCER. (2019). Available at: https://clinicaltrials.gov/ct2/show/NCT04033107 [Accessed August 15, 2022].

ASCORBIC ACID WITH CHEMOTHERAPY FOR INELIGIBLE BLADDER CANCER PATIENTS. (2018). Available at: https://clinicaltrials.gov/ct2/show/NCT04046094 [Accessed August 15, 2022].

ASCORBIC ACID WITH CHEMOTHERAPY FOR INELIGIBLE BLADDER CANCER PATIENTS. (2018). Available at: https://clinicaltrials.gov/ct2/show/NCT04634227 [Accessed August 15, 2022].

ASCORBIC ACID WITH CHEMOTHERAPY FOR INELIGIBLE BLADDER CANCER PATIENTS. (2018). Available at: https://clinicaltrials.gov/ct2/show/NCT04634227 [Accessed August 15, 2022].

ASCORBIC ACID WITH CHEMOTHERAPY FOR INELIGIBLE BLADDER CANCER PATIENTS. (2018). Available at: https://clinicaltrials.gov/ct2/show/NCT04634227 [Accessed August 15, 2022].
177. Sanz-Moreno V, Gaggioli C, Yeo M, Albrengues J, Wallberg F, Viros A, et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. *Cancer Cell* (2011) 20:229–45. doi: 10.1016/j.ccr.2011.06.018

178. Becker LM, O’Connell JT, Vo AP, Cain MP, Tampe D, Bizarro L, et al. Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer. *Cell Rep* (2020) 31:107701. doi: 10.1016/j.celrep.2020.107701